Skip to content

Guideline-Informed Treatment-Personality Disorders Youth: exploring the feasibility of early intervention treatment for emerging personality disorder in adolescents

Guideline-Informed Treatment-Personality Disorders Youth: exploring the feasibility of a generic early intervention program for emerging personality disorder in adolescents

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN89488801
Enrollment
75
Registered
2022-04-25
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early intervention for emerging personality disorders in youth (12-18 years) Mental and Behavioural Disorders

Interventions

GIT-PD Youth provides a treatment framework to improve care as usual by applying a set of principles derived from existing evidence based treatments. It’s a principle-driven, common factors approach w

Sponsors

De Viersprong
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Adolescents with emerging symptoms of personality pathology 2. Aged 12 to 18 years 3. Meet the threshold for personality disorders according to the alternative model for personality disorders in DSM-5, meaning they should display moderate or more severe impairments in personality functioning (score =2) as assessed through the Semi-structured Interview for Personality Functioning DSM-5 (STiP-5.1)

Exclusion criteria

Exclusion criteria: 1. Insufficient mastery of the Dutch language 2. Severe risk of suicide requiring immediate intervention and cognitive impairment (IQ <75). The WAIS-IV will be administered when intellectual impairment is suspected 3. Meet the DSM-5 criteria for (severe) psychotic disorders, autism spectrum disorder and (severe) substance abuse

Design outcomes

Primary

MeasureTime frame
Severity of PD symptoms is measured using the Personality Inventory for DSM-5 Brief Form score (PID-5-BF) at baseline and end of treatment (on average after 26 weeks)

Secondary

MeasureTime frame
1. Symptoms of anxiety are measured using the Generalized Anxiety Disorder- 7 score (GAD-7) at baseline and end of treatment (on average after 26 weeks) 2. Symptoms of depression are measured using the Patient Health Questionnaire-9 score (PHQ-9) at baseline and end of treatment (on average after 26 weeks) 3. Symptoms of borderline personality disorder are measured using the McLean Screening Instrument for Borderline Personality Disorder score (MSI-BPD) at baseline and end of treatment (on average after 26 weeks) 4. Emotion dysregulation is measured using the Difficulties in Emotion Regulation Scale-18 score (DERS-18) at baseline and end of treatment (on average after 26 weeks) 5. Severity of suicidal ideation is measured using the Columbia Suicide Severity Rating Scale score (CSSRS) at baseline and end of treatment (on average after 26 weeks) 6. Health-related quality of life is measured using the Kidscreen-10 score at baseline and end of treatment (on average after 26 weeks) 7. Level of personality functioning as measured by the Level of Personality Functioning Scale-Brief Form 2.0 score (LPFS-BF 2.0) at baseline and end of treatment (on average after 26 weeks)

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026